# Dinesh V. Patel

> Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.

- **Role:** President & CEO at Protagonist Therapeutics
- **Organizations:** Protagonist Therapeutics (NASDAQ: PTGX), Signal Peak Ventures (Partner Emeritus), Sai Life Sciences (Board Member, since March 2025)
- **Nationality:** Indian-American
- **Education:** B.Sc. and M.Sc. in Chemistry, S.P. University, Vallabh Vidyanagar, India, Ph.D. in Chemistry, Rutgers University, New Jersey, Post-doctoral Research (Chemistry), University of Wisconsin, Madison
- **Known for:** Led Protagonist Therapeutics from founding through the FDA approval of ICOTYDE (icotrokinra) in March 2026 - the world's first targeted oral IL-23 receptor antagonist peptide, Guided company through NDA submissions for both ICOTYDE and rusfertide in 2025, Co-founded vSpring Capital (now Signal Peak Ventures) in 2000

## Career timeline

- **1985** — Joined Bristol-Myers Squibb as a medicinal chemist
- **1993** — Joined Affymax as Director of Chemistry (combinatorial chemistry)
- **1996** — Joined Versicor (later Vicuron) as SVP Drug Discovery and Licensing
- **2000** — Co-founded vSpring Capital (now Signal Peak Ventures)
- **2003** — Co-founded Miikana Therapeutics as CEO (oncology)
- **2005** — Miikana Therapeutics acquired by Entremed; Vicuron acquired by Pfizer for $1.9B
- **2006** — Became President and CEO of Arête Therapeutics (metabolic syndrome)
- **2008** — Joined Protagonist Therapeutics as President, CEO, and board member
- **2017** — Signed license and collaboration agreement with Janssen Biotech (J&J) for icotrokinra
- **2021** — Navigated clinical hold on rusfertide; maintained team transparency through the challenge
- **2024** — Rusfertide Phase 3 VERIFY trial enrolled; REVIVE Phase 2 data showed durable hematocrit control over 3 years
- **2025** — NDA for rusfertide submitted December 2025; NDA for ICOTYDE (icotrokinra) submitted and accepted for review
- **2025-03** — Joined Sai Life Sciences board of directors
- **2026-03** — ICOTYDE (icotrokinra) received FDA approval for moderate-to-severe plaque psoriasis - first targeted oral peptide ever approved

## Achievements

- Led Protagonist Therapeutics from founding through the FDA approval of ICOTYDE (icotrokinra) in March 2026 - the world's first targeted oral IL-23 receptor antagonist peptide
- Guided company through NDA submissions for both ICOTYDE and rusfertide in 2025
- Co-founded vSpring Capital (now Signal Peak Ventures) in 2000
- Built the multi-target peptide platform at Protagonist over 17+ years
- His work at Versicor/Vicuron yielded two marketed drugs: anidulafungin (Eraxis) and dalbavancin (Dalvance); Vicuron was acquired by Pfizer for $1.9 billion
- Holds more than 100 patents and publications
- Secured $646 million in cash and equivalents for Protagonist as of year-end 2025
- Grew Protagonist's pipeline to include candidates targeting psoriasis, polycythemia vera, ulcerative colitis, Crohn's disease, and psoriatic arthritis

## Latest updates

- **2026-03** — ICOTYDE (icotrokinra) received FDA approval for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment and up to $580 million in additional milestones from J&J
- **2025-12** — Protagonist submitted an NDA for rusfertide for polycythemia vera
- **2025-03** — Dinesh Patel joined the board of directors of Sai Life Sciences Limited
- **2025-02** — Protagonist reported full-year 2025 results with $646M cash; net loss of $130.1M driven by increased R&D investment
- **2024-12** — Final Phase 2 REVIVE data for rusfertide showed durable hematocrit control below 45% for over 3 years in polycythemia vera patients

## Links

- Website: https://protagonist-inc.com
- LinkedIn: https://www.linkedin.com/in/dineshvpatel/
- Twitter/X: https://twitter.com/ProtagonistTx

---

Profile page: https://yespress.io/dinesh-patel
Published by YesPress — https://yespress.io
Last updated: 2026-06-24